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Phospholipid vesicles of less than 1 m are present in blood in physiological state and their
concentration  may vary under pathological conditions. Various names such as exosomes
(EXS)  and microparticles (MPS) have been used to designate these extracellular vesicles
(EVS).  Although EXs and MPS possibly arise from separate mechanisms, they share numer-
ous  similarities representing a challenge for their puriﬁcation and characterization. These
vesicles  generally originate from various types of cells such as red blood cells, platelets,
leukocytes  or endothelial cells but also from tumor cells. They participate in numerous
biological  processes including hemostasis. It is therefore of major scientiﬁc interest to char-Blood cells
Exosomes
Microparticles
Microvesicles
Proteomics
acterize  the protein content of these different types of EVS and that of their membranes in
order  to elucidate the essential functions of these dynamic vesicular compartments. Pro-
teomics  has been shown to be a particularly adequate tool in this study ﬁeld. This review
attempts  to link proteomic data with physiological roles and functions of blood EVS.
©  2013 The Authors. Published by Elsevier B.V. 
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.  Introduction
roteomics is of major interest for the study of blood and blood
iseases [1–11]. Plasma proteins and their modiﬁcation in var-
ous conditions have been extensively evaluated over the last
ecades in search of speciﬁc biomarkers of human diseases
12], particularly in cancer patients [13,14]. Proteomics rep-
esents nowadays the technique of choice – if not the gold
tandard – to characterize amyloidosis in tissue and plasma
amples obtained from patients with protein deposition syn-
romes [15,16].
The proteome of many  blood cells has been well charac-
erized, especially that of red blood cells (RBCs) and platelets.
he interest of applying proteomic technology to such cells is
ainly related to the fact that they share a limited capacity to
ynthesize new proteins. In this context, there is a rising value
f proteomics compared to genomics and it is not surprising
hat it has also proved effective in determining the protein
ontent of extracellular vesicles (EVS). Release of membrane
esicles, a process conserved in both prokaryotes and eukary-
tes, represents an evolutionary link, and suggests essential
unctions of this dynamic vesicular compartment [17]. Recent
tudies provided support for the concept of EVS as vectors for
he intercellular exchange of biological signals and informa-
ion [18]. EVS are able to transfer part of their components and
ontent to selected target cells, allowing cell activation, phe-
otypic modiﬁcation, and reprogramming of cell function [19].
ecause EVS circulate in the blood ﬂow, they serve as shut-
le modules and signaling transducers not only in their local
nvironment but also at distance from their site of origin.
Classiﬁcation of membrane vesicles, protocols of their iso-
ation and detection, molecular details of vesicular release,
learance and biological functions are still under intense
nvestigation. EVS have been identiﬁed in the blood circula-
ion for a long time, and have been ﬁrst considered as cell
ragments. In fact, EVS are quite heterogeneous and at least
wo main distinct types have been identiﬁed: exosomes (EXS)
nd microparticles (MPS). Both EXS and MPS are detected in
lood ﬂow, and arose out of cells such as platelets, leukocytes
nd endothelial cells [20]. EXS are small (40–100 nm in diam-
ter), spherical vesicles of endocytic origin that are secreted
pon fusion of the limiting membrane of multivesicular bod-
es with the plasma membrane. Red blood cell (RBC)-derived
esicles (REVS) have been also described in blood samples
btained from patients with many  different diseases as well as
 storage lesion from red blood cell preparations dedicated for
ransfusion [21,22]. EXS contain subproteome cytosolic pro-
eins, mRNAs  and miRNAs, and are involved in intercellular
ignaling. In contrast, MPS  bud directly from the plasma mem-
rane and their size ranges from 100 nm to 1 m (Fig. 1) [23].. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
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A model of MPS formation including translocases, lipid rafts,
various protein modiﬁcations and irreversible membrane rear-
rangements has been proposed (Fig. 2) [24,25]. MPS are not
cell fragments or “dust” without any biological function [26].
They play a role in various broad biological functions such as
thrombosis and hemostasis [20,27,28], inﬂammation [27,29] or
immunosuppression [30,31]. However, numerous similarities
exist between EXS and MPS with respect to their physical char-
acteristics and compositions. These similarities frequently
hampered the separation and puriﬁcation of these EVS in body
ﬂuids and brought confusion in the scientiﬁc literature. In this
review, we will mainly focus on blood EVS, with a particular
emphasis on platelet and RBC EVS, as well as on MPS  released
during storage of blood units. For clarity purposes, the term
EVS will be used in the following sections, grouping both MPS
and EXS.
Quantiﬁcation, proteomic analysis as well as the biol-
ogy of RBC-derived EVS (REVS), platelet-derived EVS (PEVS),
leukocyte-derived EVS (LEVS), and of endothelial cell-derived-
EVS (EEVS) are different, even if they share many  common
determinants. This review will present proteomic data that are
“speciﬁc” for each type of EVS and then, will give insights onto
the physiology of the various forms of EVS that are normally
present in the blood or in blood products.
2.  Quantiﬁcation  and  isolation  of  blood
vesicles
A variety of techniques is commonly used to study EVS (Fig. 3).
Traditionally, a limited set of technologies has been used
to characterize micro- and nano-vesicles with more  tech-
niques being available to the micro sized particles [32]. These
include: ﬂow cytometry, dynamic light scattering (DLS), elec-
tron microscopy [33,34] or enzyme linked immune-sorbent
assays (ELISA) [35–37]. Most widespread is ﬂow cytometry;
commercial ﬂow cytometry typically has a lower practi-
cal size limit (for polystyrene beads) of around 300 nm at
which point the signal is indistinguishable from the base-
line noise level. Whilst this detection limit can be extended
with the use of ﬂuorescent labels, at lower sizes the ability
to accurately size such particles is quite limited. Dynamic
light scattering has also been used in this application,
but being an ensemble measurement, the results comprise
either a simple z-average (intensity weighted) particle size
and polydispersity, or a very limited-resolution particle size
distribution proﬁle [38,39]. Electron microscopy is a useful
research tool for studying micro- and nanovesicles but at the
expense of capital running costs, extensive sample prepara-
tion [40].
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Fig. 1 – (A) Formation of extracellular vesicles from spicules of echinocytes (confocal differential interference contrast
microscopy, magniﬁcation 4000×). (B) A single red blood cell derived (micro-)vesicle surrounded by nanovesicles
(transmission electron microscopy, magniﬁcation 67 000×).
Most frequently, EVS are counted in biological samples by
ﬂow cytometry [21,41,42]. Several authors have pointed out
that despite ﬂow cytometry is the technique of choice for
evaluation of EVS, it is limited by lack of adequate standardiza-
tion [43]. Preanalytical as well as analytical issues have been
evaluated in detail by Yuana et al. [44]. Preanalytical parame-
ters were also studied in our laboratory, when measuring EVS
in stored blood products: in addition to the ﬂow cytometry
parameters chosen for the numbering of EVS, we observed that
many preanalytical variables have to be taken into account
(diluents used, temperature, vortexing duration, etc.) [45,46].
In addition, Mullier et al. recently evaluated many aspects of
the prenalytical conditions as well as pending issue that has
to be considered when measuring EVS in blood samples [47].
Because REVS express transmembrane proteins such as
band 3, glycophorins, or blood group antigens, it is quite con-
venient to use speciﬁc antibodies raised against glycophorin A,
CD47 or other blood group speciﬁc antigens for ﬂow cytometric
purposes. The expression of negatively charged phospholipids
(surface phosphatidylserine) at the external part of the vesi-
cles membrane can be explored by using annexin V as a
ligand. However, standardization is mandatory in order to
be able to compare data from different sets of experiments,
to compare normal individuals with patients and to com-
pare data from different laboratories. Recently, Xiong et al.
presented a standardized approach based on quantitative
ﬂow cytometric technique [48]. The enumeration of REVS is
made possible by using a ﬁxed number of different-sized cal-
ibration beads spiked into each sample. The master bead
mixture allowed deﬁning the relative side and forward light
scatter properties of the EVS events and enhanced the accu-
racy of the enumeration process. Such an approach certainly
may also prove useful to measure EVS that derives from
endothelial cells, leukocytes or platelets. Numbering of PEVS
is a challenge. Validation of the usefulness of cytometry to
analyze PEVS was provided by Leong et al. who combined
ﬂow cytometry and atomic force microscopy [49]. In addi-
tion, the authors demonstrated that atomic force microscopy
allows performing nanoscale measurements of individual
PEVS events isolated by ﬂow cytometry. This method provided
the ﬁrst quantitative nanoscale images of PEVS ultrastructure.Chandler et al. evaluated methods to number PEVS in fresh
and frozen aliquots of plasma as well as in fresh and frozen
aliquots of platelet-rich plasma [50]. They measured platelet
(CD41+) and annexin V+, and were able to determine PEVS in
blood samples from normal individuals. Platelet-rich plasma
from healthy individuals contained 730 000/l total EVS based
on light-scattering measurements, and a median of 27 000/l
of those EVS were of platelet origin. They also provided
emphasis on the importance of preanalytical issues show-
ing that freeze–thawing has variable effects on EVS counts,
depending on the sample preparation used. For instance, it
has been reported that the centrifugation protocols inﬂuence
the EV counts [45,48].
Strasser et al. reported a comparison analysis of three
different methods for the quantiﬁcation and characteriza-
tion of PEVS [51]. The authors, in their study, analyzed
PEVS from 31 healthy blood donors and compared pre-
and postdonation results of donors with data of platelet-
pheresis products by three different methods; PEVS counts
were analyzed by ﬂow cytometry using calibrated beads of
deﬁned diameter and annexin V-ﬂuorescein isothiocyanate
and CD41-phycoerythrin staining, whereas PEVS activity was
tested by prothrombinase assay and, ﬁnally, a procoagulant
phospholipid-dependent clotting time assay was used. The
results showed a concentration of PEVS that was more  than
threefold higher in single-platelet units compared to double-
platelet units. The prothombinase assay and the procoagulant
clotting assay also revealed a signiﬁcant higher PEVS activ-
ity in single platelet units compared to double platelet units.
These results are important for the transfusion medicine com-
munity; they conﬁrm that various procedures may results in
the production of different products.
An alternative approach for measuring EVS is nanoparti-
cle tracking analysis (NTA) [44,52,53]. In nanoparticle tracking
analysis, the size is derived from the measure of Brownian
motion of EVS in a liquid suspension [44,52]. This technol-
ogy has been successfully applied for the analysis of EVS
derived from placenta, and allows speciﬁc EXS and EVS in
the range of 50–1000 nm in liquid suspension. On the con-
trary of DLS that measures all the particles at the same
time, NTA visualizes individual particle and counts them in
t r a n s l a t i o n a l p r o t e o m i
Fig. 2 – Model of formation of microparticles. The
phospholipid organization of the membrane is under the
control of three enzymes: ﬂippase, ﬂoppase and
scramblase. (A) In resting cells, ﬂippase internalizes
negatively charged phospholipids and maintains the
asymmetry of the phospholipid bilayer. Floppase and
scramblase are inactive, and the cytoplasmic calcium
concentration is low. (B) Upon activation, intracellular
calcium concentration increases, ﬂippase is inhibited while
ﬂoppase and scramblase are activated. Floppase
externalizes phosphatidyserine, a negative phospholipid,
and scramblase translocates phospholipids non-speciﬁcally
through the membrane resulting in the loss of
phospholipid asymmetry. (C) Increased intracellular
calcium also activates proteases that cleave the
cytoskeleton; the membrane become less rigid and can bleb
resulting in the formation and release of vesicles
Reprinted from [22], with permission from S. Karger. c s 1 ( 2 0 1 3 ) 38–52 41
real-time. NTA also provides high-resolution particle size dis-
tribution proﬁles and concentration measurements. However,
NTA is time consuming and the detection of small particles
is underestimated when larger particles are present [44]. The
technique is commercially available (NanoSight Ltd., Ames-
bury, UK; www.nanosight.com).
Various approaches have been developed for isolating
blood EVS. The particles can be immuno-adsorbed on sur-
faces using speciﬁc antibodies, using different centrifugation
approaches with or without density gradients, or as recently
reported using cell sorting [54]. In their study, Bosman et al.
isolated EVS from whole blood by differential centrifuga-
tion followed by ﬂuorescence-activated ﬂow cytometry. They
removed intact cells by low speed centrifugation from cit-
rated blood, and vesicles were isolated from the supernatant,
concentrated and washed with phosphate-buffered saline by
centrifugation. The EVS were then stained with speciﬁc anti-
bodies in order to label REVS and PEVS, respectively. Finally,
EVS were sorted on a ﬂow cytometer, and analyzed using pro-
teomic tools.
3.  Proteomics  of  blood  vesicles
Proteomics is an ideal tool to study EVS [55,56]. The number
of papers published on this topic is rapidly increasing. Pro-
teomics has been used to evaluate EVS from mesenchymal
stem cells [57], from tumor cells [58,59], in ascite of patients
presenting with colon cancer [60], from HIV-infected lympho-
cytes [61], in saliva, in urine [62,63], in amniotic ﬂuid [64]
or human cerebrospinal ﬂuid [65], just to cite the expend-
ing ﬁeld of research covered by different groups interested in
the study of EVS. The technique has been also successfully
applied to the evaluation of blood EVS [66,67] as performed
by Bastos-Amador et al. who analyzed EVS from plasma of
healthy donors and showed a remarkably high variability in
the protein content of EVS from different donors [68].
3.1.  Proteomics  of  red  blood  cell-derived  vesicles
Differentiation of erythroblasts into mature RBC is a com-
plex mechanism, and many  steps have been described. The
ﬁnal pathway leads to the transformation of reticulocytes into
circulating RBCS. Carayon et al. analyzed the composition of
EXS released by reticulocytes during their differentiation [69].
Several mechanisms are involved in the process leading to
maturation of reticulocytes into mature RBCS and resulting
in the synthesis of large amounts of hemoglobin as well as in
the elimination of numerous cellular components. By combin-
ing proteomic and lipidomic approaches, the authors observed
alterations in the composition of the EXS retrieved over the
course of a 7-day in vitro differentiation protocol, and pro-
posed a model in which EXS are involved in speciﬁc pathways
of cellular differentiation and maturation.
Bosman et al. presented pioneering proteomic investiga-
tions of EVS isolated from RBCS [70–72], and of EVS isolated
from plasma [54]. In these series of studies, RBC membrane
and EVS membrane were compared, allowing the identiﬁca-
tion of several proteins differentially expressed between the
two types of samples. Furthermore, the authors were able
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Fig. 3 – Technical approaches for microparticle investigation. Combination of these methods are most frequently used for
vesicle characterization.
to characterize the effects of cellular aging on RBCS in vivo.
They compared the proteome of REVS with that of the RBCS
membrane separated according to cell age. They observed the
presence of band 3 and actin in the REVS but the absence of
almost all other integral membrane and cytoskeletal proteins.
They also identiﬁed speciﬁc alterations in band 3 aggregation
and degradation related to aging and compatible with a unique
RBC aging process, the mechanism of which being speciﬁ-
cally band 3-centered. Finally, their results pointed out that
the age-related recruitment of plasma proteins, proteins of
the ubiquitin–proteasome system, and small G proteins to the
RBC membrane supports the hypothesis that changes and/or
degradation of band 3 is involved in vesiculation [54].
Under the same period, Kriebardis et al. have followed the
proteome of REVS during storage of EC [73]. They found that
microparticles contained Hb and modiﬁed Hb, and mainly
proteins with MW lower than 70 kDa. REVS are depleted of
spectrins and cytoskelateal proteins such as proteins 4.1 and
4.2, and contain lipid raft proteins. Because of the absence of
protein 4.2, they suggested that the subpopulation observed
concerns proteins that are not band3-cytoskeletal linked (or
we may also speculate that this subpopulation contains mem-
brane proteins originally linked to the cytoskeleton and that
were released after various lesions). As shown by Bosmanet al., accumulation of band 3 aggregates is observed, espe-
cially at the end of the storage period 54. Moreover, they probed
the level of protein oxidation (carbonylation) that was signiﬁ-
cantly higher in vesicles, compared to originated membranes,
up to 21 days of storage. Then, the level of oxidation drasti-
cally decreased, which has been attributed to the depletion of
highly carbonylated proteins. They concluded on the ability of
RBCs to get rid of harmful materials by vesiculation.
In our laboratory, we evaluated REVS from RBC stored
in blood banking conditions [74] and analyzed their oxi-
dation patterns by evaluating carbonylation as a hallmark
of protein oxidative lesions [75]. In order to improve global
RBC protein carbonylation assessment, subcellular fraction-
ation has been performed, allowing to study four protein
populations that were (i) soluble hemoglobin, (ii) hemoglobin-
depleted soluble fraction, (iii) integral membrane and (iv)
cytoskeleton membrane protein fractions. In addition, car-
bonylation in REVS has been investigated. We observed
that carbonylation in the cytoskeletal membrane fraction
increased remarkably between day 29 and day 43, and that
protein carbonylation within MPS released during storage
showed a two-fold increase along the storage period. Taken
together, a scheme of protein oxidation has been proposed
(Fig. 4), suggesting a cumulative aspect of the storage lesion: a
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ellular compartment-based evolution of global carbonylation
n stored RBCS, an increasing elimination of harmful car-
onylated proteins through microvesiculation and a potential
ole of hemichrome-induced cytoskeleton oxidation in this
limination process. The oxidative pattern in REVS observed
n this study (level of carbonylation higher at the end of the
torage) differs from the one published by Kriebardis et al.
73]. In their study, they normalized the oxidation level to
he corresponding RBC membranes, which may explain the
ifferences in case of accumulation of oxidized proteins at
he membranes. Delobel et al. also identiﬁed mechanisms
f oxidation of proteins and postulated that REVS may have
 role, as cargos leading to their elimination [75]. Finally,
he group of Bosman provided very recently interesting data
ealing with the physiology of RBC removal and alloimmu-
ization [76]. The authors investigated if RBC storage leads to
he increased expression of non-physiological antigens, and
or that purpose, used immunoprecipitation, testing RBCS
nd REVS from blood units of increasing storage periods
ith patient plasma containing RBC autoantibodies. The
mmunoprecipitate was analyzed using proteomic tools. With
uch an approach, the authors observed that patient plasma
utoantibody binding increased with RBC storage time,
hich was not the case with healthy volunteer plasma, and
howed that pathology-associated antigenicity changes with
torage. They also identiﬁed several membrane proteins as
andidate antigens (namely band 3, adducing, ankyrin, band
.1, band 4.2 and other protein of the band 3 complex) for
mmunization. The protein complexes that were precipitated
y the patient autoantibodies were different whether RBCS or
esicles formed during RBC storage were used, indicating that
he storage-associated REVS have a different immunization
otential. Soluble immune mediators including complement
actors were present in the patient plasma immunoprecipi-
ates, but not in the controls. The fascinating observations
ade by the group of Bosman support the theory that dis-
urbed RBC aging during storage of blood units contributes
o transfusion-induced alloantibody and autoantibody
ormation.
Using ﬂow cytometry analysis, Almizraq et al. observed a
igniﬁcant increase in the mean number of EVS per mL  during
torage, with signiﬁcant decreases in the amount of phospho-
ipids and total lipids within the RBC membrane. These results
learly indicate that lipidomics of the storage lesion of RBCS
s certainly a new avenue of research [77].
The proteome of REVS from patients with beta-
halassemia/hemoglobin E has been explored by
haichompoo et al. [78]. In these patients, aggregability
nd oxidative damage of RBCS, combined with platelet activa-
ion and increased amount of REVS may provoke thrombotic
vents. The authors evaluated the number of EVS, the oxida-
ive stress status, the procoagulant activity, as well as the
roteome of EVS obtained from patients. By ﬂow cytometric
nalysis, the number of phosphatidylserine-bearing EVS was
igniﬁcantly higher as compared to controls. The high levels
f EVS did not only correlate with the increase of procoagulant
ctivity but also with the increase of platelet counts. These
VS corresponded to two major populations: REVS and PEVS.
roteome analysis (two-dimensional gel electrophoresis
ollowed by mass spectrometry) identiﬁed about 30 proteins c s 1 ( 2 0 1 3 ) 38–52 43
with modiﬁed levels in these patients (increased levels of
peroxiredoxin 6, apolipoprotein E, cyclophilin A and heat
shock protein 90), suggesting that the oxidative damage in
RBC and platelets potentially induces production of EVS
with altered proteome that may facilitate thromboembolic
complications.
3.2.  Proteomics  of  platelet-derived  vesicles
State of the art of platelet proteomics has been recently
reviewed [79–82]. A number of investigations focused on stud-
ies using subproteomic strategies to analyze speciﬁc platelet
conditions (resting or activated), compartments (membrane,
granules and MPS) or fractions (phosphoproteome or glyco-
proteome) [83–85]. More speciﬁcally, the proteome of PEVS has
been the object of proteomic studies. Gracia et al. found that
PEVS contain membrane surface proteins such as GPIIIa, GPIIb,
and P-selectin, as well as other platelet proteins such as the
chemokines CXCL4 and CXCL7 [86]. In another study, Jin et al.
compared the proteome of PEVS with that of plasma using
two-dimensional gel electrophoresis and mass spectrometry
[87]. They were able to identify 83 different proteins that were
not reported in the plasma proteome. Dean et al. presented
results of proteomic studies evaluating PEVS released by acti-
vated platelets [88]. In this study, PEVS were separated by gel
ﬁltration chromatography into 4 size classes to facilitate iden-
tiﬁcation of active protein and lipid components, and proteins
were separated using two-dimensional gel electrophoresis,
liquid chromatography, and identiﬁed by tandem mass spec-
trometry. The authors observed that PEVS of different sizes
signiﬁcantly differ in the content of plasma membrane recep-
tors and adhesion molecules, chemokines, growth factors and
protease inhibitors. The thousands of platelet proteins and
interactions discovered so far by these different powerful pro-
teomic approaches represent a precious source of information
for both basic science and clinical applications in the ﬁeld of
platelet biology.
3.3.  Proteomics  of  leukocyte-derived  vesicles
The protein characterization of LEVS is still largely unex-
plored. Furthermore, many  preanalytical difﬁculties should be
taken into account, because of the great diversity of leukocytes
in blood circulation. It is therefore mandatory to purify each
different type of LEVS using speciﬁc expressed CD antigens. A
ﬁrst attempt of deciphering the proteome of B-cell LEVS has
been published by Wubbolts et al., ten years ago [89]. In this
study, highly puriﬁed human B cell-derived EVS were analyzed
by mass spectrometry which revealed the presence of major
histocompatibility complex class I and class II, heat shock cog-
nate 70, heat shock protein 90, integrin alpha 4, CD45, moesin,
tubulin (alpha and beta), actin, G(i)alpha(2), and a multitude
of other proteins. EVS appeared to be enriched in cholesterol,
sphingomyelin, and ganglioside GM3, lipids that are typically
concentrated in detergent-resistant membranes.
LEVS of HIV-1-infected and -uninfected lymphocytic H9
cells were evaluated by Li et al. [61]. Using the technique of
stable isotope labeling by amino acids in cell culture (SILAC),
the authors compared protein expression patterns in the EVS
compartment of HIV-1-infected and -uninfected lymphocytes.
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Fourteen proteins were found to be differentially expressed in
the LEVS fraction of HIV-1-infected cells versus -uninfected
controls. Three immunomodulatory molecules were repro-
ducibly identiﬁed and included ADP-ribosyl cyclase 1 (CD38),
l-lactate dehydrogenase B chain, and annexin V. This study
revealed that LEVS released from HIV-1-infected cells are
composed of a unique and quantitatively different protein
signature and harbor regulatory molecules that impact the
processes of cellular apoptosis.
In patients with B-cell malignancy, accumulation of LEVS
have been observed and analyzed using proteomic tools by
Miguet et al., in order to identify speciﬁc biomarker capa-
ble of diagnosing difﬁcult cases such as leukemic phase of
non-Hodgkin lymphoma [90,91]. These studies allowed the
identiﬁcation CD148, a membrane receptor with phosphatase
activity, as a discriminating biomarker candidate. For conﬁr-
mation purposes, ﬂow cytometry analyses were performed on
158 patients and 30 controls revealing that CD148 was overex-
pressed in mantle cell lymphoma as compared to other B-cell
neoplasms.
3.4.  Proteomics  of  endothelial  cell-derived  vesicles
Until now, a few proteomic studies have been published
on the proteome of EEVS. Nevertheless, EEVS have been
characterized at the proteome level by Banﬁ et al. [92].
Mass spectrometry analyses revealed the presence of newly
described proteins such as metabolic enzymes, proteins
involved in adhesion and fusion processes, members of
protein folding event, cytoskeleton associated proteins and
nucleosome. In an interesting study, Liu et al. provided infor-
mation not only on proteomics of EEVS but also on the changes
of the protein content in the endothelial cells after stimulation
and EEVS release [93]. A direct correlation between the pro-
teins that form EEVS and tumor necrosis factor--activated
endothelial cells was observed.
4.  Biology  of  blood  vesicles
The biology of REVS, PEVS, LEVS, and of EEVS is depend-
ent of the cells from which they originate. Nevertheless,
many  physiological properties, such as their role in ﬁbrino-
lysis, may be shared by EVS deriving from different cellular
origin, as demonstrated for LEVS and EEVS. However, when
generation of plasmin is analyzed in more  details, it was
possible to demonstrate that LEVS expressed urokinase-type
plasminogen activator activity whereas EEVS are presenting
tissue plasminogen activator and tissue plasminogen activa-
tor/inhibitor complexes [94].
The forces that maintain cellular and adhesive forces of
the cellular membrane has been studied in details, both the-
oretically [95] and in physiological condition [96]. Thus, the
remodeling of the RBC membrane that maintains its bicon-
cave shape has been deciphered [97]. Finally, the physical
forces involved in the membrane structure has been stud-
ied, and a model resulting from different dynamic forces has
been evaluated allowing to better understand the ﬂuctuations
of the membrane leading to the formation of a normal RBC i c s 1 ( 2 0 1 3 ) 38–52
(discocyte), to stomatocyte and to echinocyte (the form of RBC
leading to the formation of EVS) [98].
Under normal conditions, REVS account for approximately
7.3% of EVS found in whole blood. The other populations
consist of particles derived from platelets (38.5%) and EVS
resulting from endothelial cells (43.5%) [48]. Many  compre-
hensive studies have been published this last decade on the
various aspects of the biology of blood EVS [99], and their
roles in physiology as well as in physiopathology have been
explored in details.
Here, a brief summary of the accumulating knowledge on
blood EVS will be presented.
4.1.  Red  blood  cell-derived  vesicles
REVS formation has been described as part of RBC senes-
cence [71] and also proposed as a part of an apoptosis-like
form in these cells [100]. This “ageing” process of RBC was
observed during storage in blood bank condition [22,74,101].
During their 120 days of lifespan, RBCS lose approximately
20% of their volume through vesicles emission whereas their
hemoglobin concentration increases by 14% [102]. Vesicula-
tion would be a mean for RBCS to get rid of speciﬁc harmful
agents such as denatured hemoglobin, C5b-9 complement
attack complex, band 3 neoantigen and IgG that tend to accu-
mulate in RBCS or on their membrane during their lifespan
[71,101,103]. The release of REVS plays a protective role that
allows RBCS to clear away dangerous molecules, such as oxi-
dized proteins [75], and thus, preventing their early removal
from blood ﬂow. In the other hand, REVS could promote
removal of RBCS by accumulating CD47 which is an inte-
gral membrane protein present on RBC’s surface, acting as
a marker of self. Thanks to CD47, normal RBCS are recog-
nized as self by macrophages (through their signal regulatory
protein ) and phagocytosis is inhibited. Senescent or dam-
aged RBCS whose CD47 expression is reduced by shedding
of REVS enriched in CD47 would no longer be recognized as
self and thus be eliminated by macrophages [104–106]. Still in
the context of RBC aging process, two main models result-
ing in microvesiculation have been proposed, the eryptosis
model and the band 3 clustering. The term “eryptosis” has
been introduced a few years ago by Lang’s group [100]. It
describes mechanism similar to apoptosis of nucleated cells
in response to various stresses but applied to RBCS. Inﬂux of
ionic calcium through nonspeciﬁc cation channels leads to
activation of several enzymes such as calpain or scramblase.
Reasons triggering this calcium intake are largely unknown
but alteration of nonspeciﬁc cation channels is often men-
tioned as a possible cause [107,108]. The band 3 clustering
model is characterized by protein oxidation. The oxidation of
hemoglobin contributes to hemichrome formation, which is
constituted of Hb derived products (likely met-hemoglobin)
linked to the inner leaﬂet, followed by the clustering and
aggregation of band 3 multimers in the membrane [109]. Band
3 clustering forms or uncovers senescent neoantigens, prob-
ably because of relatively small structural modiﬁcations that
are recognized by naturally occurring autologous IgG with sub-
sequent complement activation [110]. Both models share the
same ﬁnal outcome, which is phosphatidylserine external-
ization on RBCS membrane and degradation of cytoskeleton
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Fig. 4 – Hypothesis of oxidation-driven vesiculation in stored RBCS. (1) RBC antioxidant defenses prevent protein
carbonylation by reducing reactive oxygen species (ROS) into less reactive intermediates. After a certain storage period,
these defenses are exceeded by the oxidative stress and protein carbonylation occurs on both soluble and membrane
proteins. (2) Carbonylated proteins are recognized and degraded by the 20S proteasome. (3) Over-oxidized proteins crosslink
and cannot be degraded by proteasome anymore, inhibiting degradation of fairly oxidized proteins as well as other
damaged proteins due to steric obstruction. (4) Oxidized hemoglobin aggregates as hemichromes and binds to and alters
band 3 conformation. (5) Hemichromes heme autoxidation produces ROS which induces cytoskeleton and membrane
protein oxidation. (6) Membrane vesiculation allows elimination of altered band 3 and oxidized membrane proteins.
Reprinted from [75], with permission from Elsevier.
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[roteins followed by modiﬁcation in the phosphorylation sta-
us of band 3 (Fig. 4) [75]. Based on recent data, a clearer
icture of the molecular mechanisms underlying this pro-
ess is emerging: oxidative damage induces the binding of
emoglobin to band 3, activation of calcium-dependent per-
eable channels, phosphorylation of key player proteins and
ggregation of band 3 leading to vesiculation. This process
ives sufﬁcient membrane ﬂexibility resulting in REVS for-
ation and release. The hypothesis of an oxidative stress
eing involved in RBCS storage lesions has been reinforced
y the studies of Stowell et al. [111]. By adding ascorbic acid
olution to RBCs during storage, the authors observed a ben-
ﬁcial effect on recovery and immunogenicity of RBCs after
ransfusion, but not cytokine induction. They also demon-
trated a signiﬁcant decrease in EVS formation. Thus, the
ddition of ascorbic acid (or other antioxidants) to human
BCs may have beneﬁcial effects. Almizraq et al., by assessing
BCs throughout storage also observed signiﬁcant increases
n percent hemolysis, while signiﬁcant decreases in ATP con-
entrations as well as the mean corpuscular hemoglobin
oncentration [77,112]. The metabolic deregulation has been
dentiﬁed during RBC aging in vivo [113–116], and in vitro
117,118], resulting in the impairment of the potassium pumpsand in the subsequent loss of modulation of calcium homeo-
stasis [119]. Increased intracellular levels of calcium appeared
to promote vesiculation, even if the eryptosis-like phenomena
is also induced by a calcium-independent fashion by starva-
tion [120].
EVS have been observed in blood storage as well as in differ-
ent hematological diseases that have been recently reviewed
[21,22]. Brieﬂy, REVS are involved in clinical situations char-
acterized by hemolysis or endothelial activation. In sickle
cell disease, the abnormal hemoglobin S adds to the mem-
brane instability and favors the development of EVS [121]. In
this disease, EVS number correlates to the rate of intravas-
cular hemolysis and the degree of coagulation activation
[122,123] and deﬁnes subclinical phenotypes with enhanced
complications [124]. Phosphatidylserine-positive REVS poten-
tiate thrombin generation [122,123,125] through factor XI
activation [28,122,126]. However, other investigators identiﬁed
activated factor XII as being the key player in the coagula-
tion cascade [127]. In paroxysmal nocturnal hemoglobinuria,
complement activation may be involved in EVS generation
which contributes to the thrombotic proﬁle of these patients
[21,128–130]. In stem cell transplants, REVS may be useful in
distinguishing acute graft-versus-host disease from infection
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or sepsis [131]. However, other types of EVS are elevated in
such patients [132,133]. In malaria, rates of REVS are also cor-
related with the degree of parasitemia and the severity of the
infection [133,134].
During RBC storage, many  biochemical changes happen,
referred as “storage lesions” including RBCS membrane mod-
iﬁcations (it becomes more  rigid), lipid rafts rearrangement,
disruption of phospholipids asymmetry and EVS release
[4,71,135]. The accumulation of EVS during blood storage is
well described [74]. Recently, we  identiﬁed that these EVS have
factor XI dependent procoagulant properties and that they are
able to initiate and propagate thrombin generation [28]. EVS
from stored RBCS also carry blood group antigens that may
play a role in alloimmunization [41].
4.2.  Platelet-derived  vesicles
Platelet production is a complex process [136], beginning
within the bone marrow. Different molecular mechanisms are
involved in the formation of platelets from megakaryocytes
[137], leading to the splitting of large platelets which can
also be considered as megaparticles. Platelets in circulation
release both large vesicles that are plasma membrane-derived
microparticles and small ones that represent multivesicular
body-derived EXS [138]. The distinction between these two
populations of PEVS is difﬁcult because of an overlap in their
molecular properties and in their sizes. Furthermore, as PEVS
are released through several induction pathways, different
types of PEVS may be produced, each one bearing its mech-
anism of action. In a paper dealing with the biology of PEVS,
Varon et al. reviewed the extra-hemostatic effects of PEVS
and presented the possible roles of PEVS other than participa-
tion in blood coagulation [139]. In summary, they showed that
PEVS express and transfer functional receptors from platelet
membranes, increase expression of adhesion molecules on
cells, stimulate the release of cytokines, activate intracellular
signaling pathways, alter vascular reactivity, induce angio-
genesis, and are involved in cancer metastasis. They also
mentioned that a high PEVS level is highly correlated with
aggressive tumors and a poor clinical outcome. PEVS also
have important physiopathological role in patients presenting
with type-II heparin induced thrombocytopenia [140]. PEVS
participate in several homeostatic multi-cellular processes
[141], such as hemostasis, maintenance of vascular integrity,
and immunity, but they also have tasks in thrombotic [142],
inﬂammatory diseases [143] and cancer progression [144]. As
perfectly coined by Mause in an invited editorial, PEVS have
a hegemonic role in atherogenesis [145]. PEVS are also gen-
erated when platelets are prepared for transfusion [51], and
investigators recently demonstrated that these PEVS are not
removed by the various ﬁlters that are used for leukoreduction
[146]. A stimulating new hypothesis is potential role of PEVS as
a mediator of neurogenesis. Speciﬁcally, factors from platelets
and their PEVS may promote neo-neurogenesis by stimulat-
ing endogenous neural stem cells proliferation, migration and
differentiation, and by stimulating niche angiogenesis and the
release of neurogenic signals from endothelial cells and astro-
cytes [147]. i c s 1 ( 2 0 1 3 ) 38–52
4.3.  Leukocyte-derived  vesicles
LEVS represent only a small proportion of blood EVS, but
bear important physiological properties. As mentioned, LEVS
express markers from their parental cells (neutrophils, mono-
cytes/macrophages, and lymphocytes) and are therefore quite
heterogeneous. They harbor membrane and cytoplasmic pro-
teins as well as bioactive lipids notably related to coagulation
and inﬂammation. They may carry tissue factor or coagulation
inhibitors and, as a result, may participate in hemosta-
sis and pathological thrombosis [148]. LEVS also have both
pro-inﬂammatory and anti-inﬂammatory properties and are
clearly involved in a number of biological processes. EVS
derived are released from polymorphonuclear neutrophils EVS
upon activation. These EVS interfere with the maturation of
monocyte-derived dendritic cells [149] and down-modulate
the inﬂammatory response of human macrophages and den-
dritic cells exposed to TLR-2 and -4 ligands [150]. This
down-modulation appeared to be mediated via the engage-
ment and activation of the Mer receptor tyrosine kinase
(MerTK), as well as by an immediate Ca2+ ﬂux and a rapid
release of TGF-beta1.
LEVS show a complex relation with endothelial cells, at
the same time improving the endothelial function or on the
contrary inducing an endothelial dysfunction. Consequently
LEVS are largely implicated in all stages of atherosclerosis
and circulate at a high level in the bloodstream of patients
with high atherothrombotic risk. LEVS modify the endothelial
function and promote the recruitment of inﬂammatory cells
in the vascular wall both representing necessary processes for
the progression of the atherosclerotic lesion. In addition, LEVS
favor the neovascularization within the vulnerable plaque
and, when the plaque is ruptured, take part in coagulation
and platelet activation. LEVS also participate in angiogene-
sis [65]. LEVS, as well as other types of EVS – notably those
deriving from tumor cells – bind plasminogen and vectorize
plasminogen activators, leading to an efﬁcient plasmin gen-
eration and matrix metalloproteinases activation [151]. Thus,
LEVS behave as an efﬁcient catalytic surface involved in vascu-
lar and matrix proteolysis-related biological processes, acting
in many  biological processes such as ﬁbrinolysis, cell survival,
matrix remodeling, angiogenesis, and tumor metastasis.
Circulating levels of LEVS appear to be increased in adults
with chronic B-cell lymphoproliferations (chronic lymphocytic
leukemia, small cell lymphoma and mantle cell lymphoma)
[91,152] and in children with B-cell neoplasm [153]. Finally,
LEVS derived from leukemic cells probably play a pathological
role by participating to the coagulopathy that is some-
times observed in patients with acute myeloblastic leukemia
[154,155]. In a study evaluating patients with acute promyelo-
cytic leukemia (a situation characterized by serious bleeding
and thrombotic complications), Ma et al. analyzed LEVS
from 30 patients and healthy controls [156]. The morphol-
ogy of the LEVS was examined by using transmission electron
microscopy and laser scanning confocal microscopy. LEVS
were quantiﬁed and analyzed for their thrombin-generating
potential. Counts of LEVS in patients with acute promyelocitic
leukemia were elevated and were typically from promyelo-
cytic cells (CD33+, tissue factor+). The CD33+ LEVS levels
correlated with patient leukocyte counts and coagulation
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ctivation (evaluated by measuring d-dimer). Moreover, LEVS
rom patients decreased the coagulation times and induced
hrombin generation; interestingly, LEVS-associated thrombin
eneration was reduced by adding an anti-human tissue factor
ntibody, but neither with anti-factor XI nor anti-tissue factor
athway inhibitor.
.4.  Endothelial  cell-derived  vesicles
ascular homeostasis is the reﬂection of quiescent, but
ompetent endothelium. EEVS are released by endothelium
157,158]. They are now recognized as key players in a mul-
itude of biological functions necessary for the maintenance
f endothelial integrity and vascular biology. EEVS have been
emonstrated to act as primary and secondary messengers
f vascular inﬂammation, thrombosis, vasomotor response,
ngiogenesis, and endothelial survival. EEVS also induce cell
ycle arrest through redox-sensitive processes in endothe-
ial cells, thus having implications in vascular senescence
159]. These often-neglected EEVS are emerging as poten-
ially useful indicators of dysfunctioning endothelium. They
ave been implicated in many  different diseases such as pre-
clampsia in pregnancy [160], pulmonary hypertension [161],
hronic graft versus host disease [162], antiphospholipid syn-
rome [163], or vasculitis such as in Kawasaki’s syndrome
164]. They also have been detected in cancer patients in
hose circulating levels of MPS  correlate with prognosis, and
ould be used as prognostic markers for example in advanced
on-small cell lung cancer [165]. Very recently, EEVS have
een implicated as player in mitral valve disease. In a study
f patients with mitral valve disease, Ci et al. observed an
ncreased level of circulating EEVS from blood samples when
ompared to controls [166]. In addition, they also analyzed
he effects of EEVS on cells derived from human mitral valve
ndothelial cells. The authors observed modiﬁcations of the
hosphorylation of Akt, of endothelial nitric oxide synthase,
f the association of endothelial nitric oxide synthase and
eat shock protein 90, the generation of nitric oxide as well
s of the generation of superoxide anion. EEVS were signif-
cantly increased in patients with mitral valve disease. The
ncrease of EEVS also impaired the function of cells derived
rom human mitral valve endothelial cells by inhibiting the
kt/endothelial nitric oxide synthase – heat shock protein 90
ignaling pathway. CD36+ EVS have been observed as being
ncreased in the blood of obese patients, with or without type
 diabetes mellitus. Interestingly enough, CD36+ EVS origi-
ating from erythrocytes were identiﬁed as being increased
n obese type 2 diabetic patients, contrasting with the main
ource of CD36+ EVS that was of endothelial origin in obese
on-diabetic control patients [167].
.  Conclusions  and  perspectives
owadays, the study of the biology of EVS, EXS, MPS and other
xtracellular vesicles is a fascinating ﬁeld of research. This
omain is rapidly growing and the medical applications of
uch studies are at our doorstep. An International Society for
xtracellular vesicles has been created in 2012, and the annual
ongress was in Boston, April 2013. A new journal has been c s 1 ( 2 0 1 3 ) 38–52 47
launched (Journal of Extracellular Vesicles; eISSN 2001-3078),
which will be the ofﬁcial journal of the Society. The ﬁrst issue
is out of press. Proteomics, as highlighted in the last part of
this review, is certainly a tool of major importance to char-
acterize the proteins that are present in EVS. Proteomics has
shown its power in a lot of topics and applications, and EVS
is and will be one of them. However, making a list of pro-
teins is insufﬁcient to understand the multiple functions and
roles of EVS, and proteomics is not a unique solution in ﬁne.
The challenges remain the EVS isolation to obtain homoge-
nous subpopulations, the fractionation for accurate proteomic
analyses and the coupling to a functional approach, includ-
ing complementary data. Deﬁnitively EVS are not the rubbish
of the cell, and should be integrated in the cellular biology.
The future of biomarker discovery related to speciﬁc disease
will focus on EVS release in body ﬂuids from various cells. A
fascinating ﬁeld of research is open and largely dedicated to
specialists in proteomic sciences.
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